NovoCure (NVCR) Share-based Compensation (2014 - 2026)

NovoCure (NVCR) has reported Share-based Compensation for 13 consecutive years, with $17.0 million the latest figure, recorded in Q2 2026.

• Quarterly Share-based Compensation fell 34.93% year-over-year to $17.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $129.2 million (down 13.79% YoY) and the FY2025 annual result came in at $104.8 million, down 34.49% from the prior year.
• Share-based Compensation fell to $17.0 million in Q2 2026 per NVCR's latest filing, from $63.0 million in the prior quarter.
• Over the last five years, Share-based Compensation for NVCR reached as high as $63.0 million in Q1 2026 and fell as low as $17.0 million in Q2 2026.
• A 5-year average of $31.5 million and a median of $29.4 million in 2025 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation jumped 259.89% — and 2025, when it sank 68.42%.
• Year by year, Share-based Compensation stood at $29.8 million in 2022, then plunged by 41.45% to $17.4 million in 2023, then soared by 259.89% to $62.8 million in 2024, then plunged by 68.42% to $19.8 million in 2025, then slipped by 14.15% to $17.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $17.0 million, $63.0 million, and $19.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.